Literature DB >> 22873622

Sorafenib use in hepatocellular carcinoma in Japan: early experience and impact on clinical practice.

Andrew X Zhu1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22873622     DOI： 10.1007/bf03265491

Source DB:  PubMed          Journal:  Clin Drug Investig        ISSN： 1173-2563            Impact factor:   2.859


× No keyword cloud information.
  4 in total

1.  Liver cancer toll high in Japan.

Authors:  A Easton
Journal:  BMJ       Date:  1999-06-05

Review 2.  Evolving strategies for the management of intermediate-stage hepatocellular carcinoma: available evidence and expert opinion on the use of transarterial chemoembolization.

Authors:  J-L Raoul; B Sangro; A Forner; V Mazzaferro; F Piscaglia; L Bolondi; R Lencioni
Journal:  Cancer Treat Rev       Date:  2010-08-17       Impact factor: 12.111

3.  Clinical practice guidelines for hepatocellular carcinoma: the first evidence based guidelines from Japan.

Authors:  Masatoshi Makuuchi; Norihiro Kokudo
Journal:  World J Gastroenterol       Date:  2006-02-07       Impact factor: 5.742

Review 4.  Hepatocellular carcinoma: epidemiology and molecular carcinogenesis.

Authors:  Hashem B El-Serag; K Lenhard Rudolph
Journal:  Gastroenterology       Date:  2007-06       Impact factor: 22.682
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.